VIVUS (VVUS) Announces REVIVE Trial Results for Avanafil

VIVUS, Inc. (NASDAQ: VVUS) today announced that results from the REVIVE study were published in The Journal of Sexual Medicine (JSM), a peer-reviewed journal with broad, multidisciplinary readership. REVIVE (TA-301) was a randomized, placebo-controlled, phase 3 study evaluating the safety and efficacy of avanafil, an investigational drug currently under review by the FDA for the treatment of erectile dysfunction (ED). In addition to significant improvements in erectile function and low rates of side effects common to phosphodiesterase type 5 inhibitors, the study also found that patients who attempted intercourse within 15 minutes of dosing were successful 64%, 67% and 71% of the time with 50, 100 and 200mg of avanafil treatment, respectively, versus 27% for placebo (p < 0.0001). The data suggest that avanafil may provide a rapid-onset, well-tolerated and effective treatment option for erectile dysfunction.

An overview of the results as published in JSM is as follows:

• Following 12 weeks of treatment, without restrictions on food or alcohol, all three doses of avanafil (50mg, 100mg and 200mg) were significantly superior to placebo for all primary endpoints (p
  
• A secondary analysis using Sexual Encounter Profile, question 3 (SEP 3) to evaluate the number of successful intercourse attempts at various time points post-dosing revealed that avanafil was associated with a significant treatment response as early as 15 minutes and beyond 6 hours after dosing.
  
• Nearly 80% of all sexual attempts among patients in the 200mg dose group of avanafil had erections sufficient for intercourse.
  
• 72% of study participants had tried at least one other ED treatment.
  
• The most common side effects were headache, flushing, nasal congestion and back pain and no drug-related serious adverse events reported.
  
• The completion rate in REVIVE was 85.1% and discontinuations due to adverse events were 1.9%, 3.1%, 2.5% and 3.1% for the 50mg, 100mg, 200mg and placebo groups, respectively.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Synaptics CFO resigns amid pending ON Semiconductor merger
• Trustar Bank to acquire Forbright Bank branches for $750M in deposits
• Virtus Investment Partners names Jack Boyce to its board